Login / Signup

Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.

Faizan KhanTobias TritschlerMiriam KimptonPhilip S WellsClive KearonJeffrey I WeitzHarry R BüllerGary E RaskobWalter AgenoFrancis CouturaudPaolo PrandoniGualtiero PalaretiCristina LegnaniPaul A KyrleSabine EichingerLisbeth EischerCecilia BecattiniGiancarlo AgnelliMaria Cristina VedovatiGeert-Jan GeersingToshihiko TakadaBenilde CosmiDrahomir AujeskyLetizia MarconiAntonio PallaSergio SiragusaCharlotte Ann BradburySameer ParpiaRanjeeta MallickAnthonie W A LensingMartin GebelMichael A GrossoMinggao ShiKednapa ThavornBrian HuttonGregoire Le GalMarc A RodgerDean A Fergusson
Published in: Journal of thrombosis and haemostasis : JTH (2021)
In patients with a first unprovoked VTE, the long-term risk of recurrent VTE during extended anticoagulation is low but not negligible. Thus, clinicians and patients should be aware of this risk and take appropriate and timely action in case of suspicion of recurrent VTE. Estimates from this study can be used to advise patients on what to expect while receiving extended anticoagulation, and estimate the net clinical benefit of extended treatment to guide long-term management of unprovoked VTE.
Keyphrases
  • venous thromboembolism
  • direct oral anticoagulants
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • palliative care